Human infection with Plasmodium parasites remains a serious global health crisis, leading
to more than 600,000 deaths annually. Currently, no licensed vaccine is available to …

The parasitic disease malaria threatens more than 3 billion people worldwide, resulting in
more than 200 million clinical cases and almost 600,000 deaths annually. Vaccines remain …

In the last few decades, considerable efforts have been made toward the development of
efficient vaccines against malaria. Whole‐sporozoite (Wsp) vaccines, which induce efficient …

Each year malaria kills hundreds of thousands of people and infects hundreds of millions of
people despite current control measures. An effective malaria vaccine will likely be …

Despite continuous efforts, the century-old goal of eradicating malaria still remains. Multiple
control interventions need to be in place simultaneously to achieve this goal. In addition to …

Immunization with Plasmodium sporozoites, either attenuated or administered under the
cover of an antimalarial drug, can induce strong protection against malaria in pre-clinical …

Malaria is caused by complex protozoan Plasmodium parasites that have foiled efforts to
develop a protective vaccine. Despite this, it has been known for more than 40 years that …

In both preclinical animal studies and human clinical trials, adult females tend to develop
greater adaptive immune responses than males following receipt of either viral or bacterial …

Long-term protection against malaria remains one of the greatest challenges of vaccination
against this deadly parasitic disease. Whole-sporozoite (WSp) malaria vaccine formulations …

Live attenuated malaria vaccines are more potent than the recombinant protein, bacterial or
viral platform vaccines that have been tested, and an attenuated sporozoite vaccine against …